Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357853 | 0.86 | HPGD (0.50) | HPGDRECQLSSTR4MEN1KMT2A | |
| SCHEMBL14391516 | 0.86 | HPGD (0.50) | HPGDRECQLSSTR4MEN1KMT2A | |
| SCHEMBL25096572 | 0.81 | HRH3 (0.47) | HPGDRECQLTSHRSIGMAR1 | |
| SCHEMBL25103815 | 0.81 | HRH3 (0.47) | HPGDRECQLTSHRSIGMAR1 | |
| SCHEMBL25103818 | 0.81 | HRH3 (0.47) | HPGDRECQLTSHRSIGMAR1 | |
| SCHEMBL1911126 | 0.80 | SSTR4 (0.41) | HPGDRECQLSSTR4MEN1KMT2A | |
| SCHEMBL12409132 | 0.79 | SIGMAR1 (0.63) | HPGDRECQLSSTR4SSTR1SIGMAR1 | |
| SCHEMBL4975797 | 0.78 | ALDH1A1 (0.52) | HPGDRECQLKMT2ASMN1; SMN2SIGMAR1 | |
| SCHEMBL13321381 | 0.75 | VCP (0.49) | TSHRSIGMAR1 | |
| SCHEMBL16293101 | 0.73 | ALDH1A1 (0.49) | HPGDRECQLMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | HPGD 1278/4885RECQL 773/4885SSTR4 1248/4885 |
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | HPGD 2604/4885RECQL 1482/4885SSTR4 418/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | HPGD 2604/4885RECQL 1482/4885SSTR4 418/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | HPGD 2604/4885RECQL 1482/4885SSTR4 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.